RxDoctor Payments Data

Timothy Truman

Internal Medicine · Newark, DENPI 1952834897

Payments from drug & device makers

$1,019in general payments, 2019–2025

Across 27 payments — averaging $37.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$319
  • AstraZeneca$226
  • Johnson & Johnson$159
  • Merck$51
  • Lilly USA, LLC$47
  • Exact Sciences$42
  • plus $175 from 8 others

What the payments were for

  • Food & beverage$1,019100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,019 in reported general payments places this provider in the 75th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$126,435
Medicare patients
437
Services billed
1,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$35,524
JardianceEmpagliflozin16$19,954
MounjaroTirzepatide11$10,693
Gabapentin52$911
Desloratadine18$839
Atorvastatin Calcium50$670
Metoprolol Succinate33$564
Albuterol Sulfate HfaAlbuterol Sulfate21$527
Fluticasone Propionate31$518
Amlodipine Besylate63$435
Azelastine Hcl14$388
Levothyroxine Sodium33$377
Famotidine21$339
Duloxetine Hcl14$309
Losartan Potassium53$308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$20$19,95416 claims
Lilly USA, LLCMounjaro$47$10,69311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 477 internal medicine providers in Delaware.

Other internal medicine in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →